Drug Trial Radar · NCT06686654
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,530
Actual
Start
Nov 11, 2024
Primary completion
Jan 18, 2027
Study completion Jan 18, 2027
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older. The study will also evaluate the safety and immunogenicity of a booster vaccination using a bivalent hMPV/RSV mRNA vaccine candidate (hereafter referred to as RSV+hMPV mRNA vaccine candidate). Overall, the study is designed to address the following goals: * Assess the safety profile of the candidate formulations. * Describe the immunogenicity profile of the candidate formulations. * Select the vaccine formulations (dose) for future development. * Assess the safety and immunogenicity of a booster vaccination with the RSV + hMPV mRNA vaccine candidate administered 12 months after primary vaccination with a licensed RSV vaccine. The study duration is as follows: -Six months each for the Sentinel and Main Cohorts; up to 12 months for the Expansion Cohort, and 6 additional months for the Booster Cohort Treatment duration: * Stage 1 Sentinel Cohort: 1 intra-muscular (IM) injection. Participants will be followed for 6 months post vaccination * Stage 1 Main Cohort: 1 IM injection. Participants will be followed for 6 months post vaccination * Stage 2 Expansion Cohort: 1 IM injection. Participants in the licensed RSV vaccine arm will be followed for 12 months post-vaccination; the remainder of the participants will be followed up to 8 months post-vaccination * Stage 2 Booster Cohort: 1 IM injection 12 months post-primary vaccination. Participants will be followed for 6 months post-booster vaccination
Conditions
- Human Metapneumovirus Immunization
- Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccineBiological
Investigational hMPV/RSV vaccine administered intramuscularly
Investigational hMPV vaccine (monovalent)Biological
Investigational hMPV vaccine (monovalent) administered intramuscularly
Investigational RSV vaccine (monovalent)Biological
Investigational RSV vaccine (monovalent) administered intramuscularly
Licensed RSV VaccineBiological
Licensed RSV vaccine administered intramuscularly
PlaceboBiological
Placebo administered intramuscularly
Investigational RSV+hMPV vaccineBiological
Investigational RSV+hMPV vaccine administered intramuscularly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of unsolicited immediate systemic adverse events (AEs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Within 30 minutes after primary and booster vaccinations
- Presence of solicited injection site and systemic reactions (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Up to 7 days after primary and booster vaccinations
- Presence of unsolicited AEs (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Up to 28 days after primary and booster vaccinations
- Presence of medically attended AEs (MAAEs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Up to 6 months after primary and booster vaccinations
- Presence of serious AEs (SAEs) and AEs of special interest (AESIs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Up to 6 months after primary and booster vaccinations
- Presence of related SAEs, related AESIs, and fatal SAEs (regardless of causality) (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Throughout the duration of the study (up to approximately 24 months)
- Presence of out-of-range biological test results (Stage 1)Time frame: Up to 7 days after primary vaccination
- Presence of out-of-range biological test results (Stage 2 Booster Cohort)Time frame: Up to 7 days after booster vaccination
- hMPV A serum neutralizing antibodies (nAb) titers in Stage 1 Sentinel and Main CohortsTime frame: At pre-vaccination (Day 01) and 28 days post-primary vaccination (Day 29)
- hMPV B serum neutralizing antibodies (nAb) titers in Stage 1 Sentinel and Main CohortsTime frame: At pre-vaccination (Day 01) and 28 days post-primary vaccination (Day 29)
- RSV A serum nAb titers in Stage 1 Sentinel and Main CohortsTime frame: At pre vaccination (D01) and 28 days post-primary vaccination (D29)
- RSV B serum nAb titers in Stage 1 Sentinel and Main CohortsTime frame: At pre vaccination (D01) and 28 days post-primary vaccination (D29)
- hMPV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
- hMPV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
- RSV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
- RSV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
- hMPV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV standalone vaccine (Day 29)
- hMPV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV standalone vaccine (Day 29)
- RSV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the RSV standalone vaccine (Day 29)
- RSV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the RSV standalone vaccine (Day 29)
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Velocity Clinical Research, Phoenix- Site Number : 8400025
Phoenix, Arizona
CenExel CNS-Garden Grove- Site Number : 8400017
Garden Grove, California
National Research Institute - Gardena- Site Number : 8400005
Gardena, California
National Research Institute - Huntington Park- Site Number : 8400014
Huntington Park, California
Velocity Clinical Research - San Diego- Site Number : 8400008
La Mesa, California
Velocity Clinical Research Los Angeles- Site Number : 8400013
Los Angeles, California
National Research Institute - Panorama City- Site Number : 8400012
Los Angeles, California
Providence Clinical Research - North Hollywood- Site Number : 8400018
North Hollywood, California
Peninsula Research Associates- Site Number : 8400002
Rolling Hills Estates, California
Velocity Clinical Research - Denver- Site Number : 8400016
Englewood, Colorado
Velocity Clinical Research - Washington DC- Site Number : 8400007
Washington D.C., District of Columbia
Velocity Clinical Research - Hallandale Beach- Site Number : 8400022
Hallandale, Florida
Suncoast Research Associates - Miami - Sunset Drive- Site Number : 8400001
Miami, Florida
Velocity Clinical Research - Meridian- Site Number : 8400003
Meridian, Idaho
Velocity Clinical Research - Kansas City- Site Number : 8400015
Overland Park, Kansas
Velocity Clinical Research - Rockville- Site Number : 8400011
Rockville, Maryland
Velocity Clinical Research - Lincoln - Valley Road- Site Number : 8400023
Lincoln, Nebraska
Velocity Clinical Research - Omaha- Site Number : 8400006
Omaha, Nebraska
Velocity Clinical Research - Springdale- Site Number : 8400004
Cincinnati, Ohio
Velocity Clinical Research - Medford- Site Number : 8400024
Medford, Oregon
Velocity Clinical Research - Austin- Site Number : 8400020
Cedar Park, Texas
Velocity Clinical Research - Salt Lake City- Site Number : 8400010
West Jordan, Utah
Velocity Clinical Research - Hampton- Site Number : 8400026
Hampton, Virginia
Velocity Clinical Research - Seattle- Site Number : 8400019
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.